Evidence map›Paper›PMID 19349618›Full record

ArticleBlood2009

Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study.

Lucien Noens, Marie-Anne van Lierde, Robrecht De Bock, Gregor Verhoef, Pierre Zachée, Zwi Berneman, Philippe Martiat, Philippe Mineur, Koen Van Eygen, Karen MacDonald and 3 more

3 registry-linked trialsOpen access · bronzeAbstract readEvaluation StudyMulticenter Study
PubMed Publisher
In one paragraph

Article in Blood, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 231 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
231citing papers in PubMed, 5 pooled it
21.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01768689 nacompletednot on this mapstarted 2013, after this paper: background citation

The Effect of Active Adherence-Encouraging Interventions on Adherence to Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia - A Prospective Observational Multicenter Study (TAKE-IT)

TypeinterventionalSponsorpia raananiRan2013 to 2015Enrolled58ConditionsLeukemia, Myelogenous, Chronic, BCR-ABL Positive, Medication AdherenceArmsAdherence-encouraging interventions - Group meeting, Adherence-encouraging interventions - Individual meetings, Adherence-encouraging interventions - Monthly phone calls
NCT03454971 nacompletednot on this mapstarted 2018, after this paper: background citation

Multidisciplinary Consultation at the GHM Hospital of Grenoble (France) for the Establishment of an Oral Anti-cancer Drug Therapy : Feasibility, Security, and Evaluation of Patients' and City Health Professionals' Satisfaction.

TypeinterventionalSponsorGroupe Hospitalier Mutualiste de GrenobleRan2018 to 2020Enrolled64ConditionsCancerArmsMinOS protocol
NCT04384848 nacompletednot on this mapstarted 2019, after this paper: background citation

Evaluating Patient-Reported Outcomes Monitoring in Routine Care of Patients With Chronic Myeloid Leukemia for Increasing Adherence and Clinical Response to THerapY: The EMPATHY Pilot Study

TypeinterventionalSponsorNorthwestern UniversityRan2019 to 2022Enrolled94ConditionsLeukemia, Chronic Myeloid, CancerArmsEMPATHY Pilot
3 · Its place in the literature

Who cites it

231 citing papers in PubMed, 5 syntheses or guidelines pooled it, 610 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Guideline
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2016
    Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

171 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 9 institutions in 3 countries.

Lucien NoensUniversitair Ziekenhuis (UZ) Gent, Gent, Belgium.
Marie-Anne van Lierde
Robrecht De Bock
Gregor Verhoef
Pierre Zachée
Zwi Berneman
Philippe Martiat
Philippe Mineur
Koen Van Eygen
Karen MacDonald
Sabina De Geest
Tara Albrecht
Ivo Abraham
Matrix Research (United States) · USZiekenhuisnetwerk Antwerpen Stuivenberg · BEAZ Groeninge · BEGhent University Hospital · BEInstitut Jules Bordet · BENovartis (Belgium) · BEProvince of Antwerp · BEUniversitair Ziekenhuis Leuven · BEUniversity of Basel · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Imatinib mesylate (imatinib) has been shown to be highly efficacious in the treatment of chronic myeloid leukemia (CML). Continuous and adequate dosing is essential for optimal outcomes and with imatinib treatment possibly being lifelong, patient adherence is critical. The ADAGIO (Adherence Assessment with Glivec: Indicators and Outcomes) study aimed to assess prospectively over a 90-day period the prevalence of imatinib nonadherence in patients with CML; to develop a multivariate canonical correlation model of how various determinants may be associated with various measures of nonadherence; and to examine whether treatment response is associated with adherence levels. A total of 202 patients were recruited from 34 centers in Belgium, of whom 169 were evaluable. One-third of patients were considered to be nonadherent. Only 14.2% of patients were perfectly adherent with 100% of prescribed imatinib taken. On average, patients with suboptimal response had significantly higher mean percentages of imatinib not taken (23.2%, standard deviation [SD] = 23.8) than did those with optimal response (7.3%, SD = 19.3, P = .005; percentages calculated as proportions x 100). Nonadherence is more prevalent than patients, physicians, and family members believe it is, and therefore should be assessed routinely. It is associated with poorer response to imatinib. Several determinants may serve as alert signals, many of which are clinically modifiable.

Indexed as

Patient ComplianceAdolescentAdultAgedAged, 80 and overAntineoplastic AgentsBenzamidesCase-Control StudiesFemaleHumansImatinib MesylateLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMaleMiddle AgedPiperazinesPrevalenceAntineoplastic AgentsBenzamidesImatinib MesylatePiperazinesPyrimidines

Identifiers

PMID19349618
OpenAlexW2048809946

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.